Step right up: A biotech may soon sell an ex­per­i­men­tal med to dy­ing ALS pa­tients un­der 'Right to Try'

Dur­ing the de­bate over the new Right to Try leg­is­la­tion, a num­ber of crit­ics raised the ar­gu­ment that some com­pa­nies would try to cash in by sell­ing ex­per­i­men­tal drugs with an un­de­fined risk pro­file to des­per­ate, dy­ing pa­tients.

Brain­storm Cell Ther­a­peu­tics $BCLI ap­pears to be on track to be one of the first to test the let­ter of the law on that score.

The Is­raeli biotech has been slow­ly work­ing on a stem cell ther­a­py for ALS, or Lou Gehrig’s dis­ease. For months now, com­pa­ny ex­ecs have been hint­ing at the move, not­ing the num­ber of ALS pa­tients who have been clam­or­ing for a ther­a­py they dubbed NurOwn. And in an in­ter­view with Bloomberg, CEO Chaim Lebovits said that they’re think­ing of a price in the re­gion of the pi­o­neer­ing per­son­al­ized cell ther­a­pies that have been ap­proved.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA